Hydrogel of spirulina-derived exosomes.
Phase 2Small molecule
Hydrogel of spirulina-derived exosomes. is one of 14 small molecule programs targeting Esophagitis. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
13
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
13 competitors in Esophagitis
#DrugCompanyPhaseTrials
1Prevacid
TakedaApproved
Dexilant
TakedaApproved
Nexium
DDexcel Pharma Technologies Ltd.
Approved
Aciphex
Akero TherapeuticsApproved
Flovent
PParatek Pharmaceuticals Inc
Approved
Protonix
WWyeth-Lederle Vaccines
Approved
Pulmicort
SSalix
Approved
Alka-Seltzer
AAbbott
Approved
Abelcet
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Hydrogel of spirulina-derived exosomes.
WWest China Hospital
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- WWest China Hospital